Get the Stockscreener App
39.59
2.34%
-0.98
Veracyte Inc stock is traded at $39.59, with a volume of 230.65K.
It is down -2.34% in the last 24 hours and down -6.75% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
See More
Previous Close:
$40.57
Open:
$40.4
24h Volume:
230.65K
Relative Volume:
0.26
Market Cap:
$3.14B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-52.79
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-4.97%
1M Performance:
-6.75%
6M Performance:
+56.91%
1Y Performance:
-7.71%
1-Day Range:
$39.54
$40.58
1-Week Range:
$39.54
$45.55
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
39.66 | 3.21B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
624.47 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.28 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
698.05 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.80 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.65 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte, Inc. (VCYT) sees analyst support as Guggenheim reaffirms buy rating - MSN
Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again - Nasdaq
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate - Chartmill
Stronger‑Than‑Expected Revenue Outlook Might Change The Case For Investing In Veracyte (VCYT) - simplywall.st
Swing Trade: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantJuly 2025 WrapUp & Verified Entry Point Signals - baoquankhu1.vn
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Assessing Veracyte (VCYT) Valuation As Recent Momentum Meets An Expensive P/E Ratio - Sahm
Is Veracyte’s (VCYT) Confident Double‑Digit Revenue Outlook Altering The Investment Case For Investors? - Yahoo Finance
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating - Finviz
Centene Expands Palliative Care Access in Ohio Through Tuesday Health - Nasdaq
QRG Capital Management Inc. Sells 106,926 Shares of Veracyte, Inc. $VCYT - MarketBeat
S P Trends: Is Veracyte Inc showing insider buyingTrade Entry Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
State of Alaska Department of Revenue Takes $1.50 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Trade Recap: Is Veracyte Inc stock a value trapJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 165,094 Shares of Veracyte, Inc. $VCYT - MarketBeat
SG Americas Securities LLC Increases Stock Position in Veracyte, Inc. $VCYT - MarketBeat
Veracyte (NASDAQ:VCYT) Cut to Hold at Zacks Research - MarketBeat
Is Veracyte’s 2026 Growth Guidance And New US Launches Altering The Investment Case For Veracyte (VCYT)? - Sahm
Louisiana State Employees Retirement System Invests $1.24 Million in Veracyte, Inc. $VCYT - MarketBeat
Lung Cancer Diagnostics Market Size and Forecast 2025–2033 - Vocal
Breakout Move: What is the dividend yield of CMMBJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Volume Recap: Is Veracyte Inc. stock a top pick in earnings seasonStock Surge & Accurate Trade Setup Notifications - Bộ Nội Vụ
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $44 - 富途牛牛
Morgan Stanley initiates coverage of Veracyte, Inc. (VCYT) - MSN
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook - Investing.com Australia
Veracyte stock rating reiterated at Buy by UBS on strong revenue outlook By Investing.com - Investing.com India
Needham reiterates Buy rating on Veracyte stock after strong Q4 preannouncement - Investing.com Nigeria
Summit Creek Advisors LLC Makes New $8.52 Million Investment in Veracyte, Inc. $VCYT - MarketBeat
Veracyte stock outlook positive as Leerink reiterates Outperform rating By Investing.com - Investing.com South Africa
Veracyte stock outlook positive as Leerink reiterates Outperform rating - Investing.com India
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results - 01net
Veracyte (VCYT) Sets Ambitious Revenue Growth Targets for 2026 - GuruFocus
Veracyte (VCYT) Poised for Growth with New Product Launches in 2 - GuruFocus
BRIEF-Veracyte Outlook FY Revenue Growth 16% - TradingView — Track All Markets
Published on: 2026-01-11 01:59:58 - ulpravda.ru
Veracyte Reports Strong Q3 2025 Financial Performance - MSN
Market Wrap: Can Veracyte Inc 12V stock reach 200 price targetJuly 2025 Final Week & Precise Buy Zone Identification - Bộ Nội Vụ
Can Veracyte Inc. (12V) stock reach $200 price targetJuly 2025 Weekly Recap & AI Driven Price Predictions - Улправда
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Veracyte Inc. stock could outperform in 2025July 2025 Decliners & Low Risk Growth Stock Ideas - Улправда
Veracyte Inc (VCYT) Stock Price Today | Live Chart & News - Traders Union
Will Veracyte Inc. stock gain from lower inflationJuly 2025 Outlook & Daily Chart Pattern Signal Reports - Улправда
Published on: 2026-01-09 02:13:40 - ulpravda.ru
Operating cash flow per share of Veracyte, Inc. – DUS:12V - TradingView — Track All Markets
Update Recap: How interest rate cuts could boost Veracyte Inc. stock2025 Analyst Calls & Technical Pattern Based Signals - Улправда
Aug Chart Watch: How interest rate cuts could boost Veracyte Inc. stockMarket Growth Report & Verified Swing Trading Watchlists - Улправда
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):